S90652 in Paediatric Hypertension

Acceptability, Safety, Pharmacokinetics and Effects on Blood Pressure of a Daily Dose of 0.025 to 0.135 Milligram Per Kilogram of S90652, a Paediatric Formulation of Perindopril, in 2-16 Years Old Hypertensive Children - 3 Month Study

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00202553

Enrollment

Registered

2005-09-20

Start date

2003-07-31

Completion date

2006-12-31

Last updated

2018-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

The aim of the study is to assess the acceptability, safety and pharmacokinetics and effects on blood pressure of a paediatric formulation of perindopril given in hypertensive children

Interventions

DRUGPerindopril

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

2 Years to 16 Years

Healthy volunteers

Inclusion criteria

* Hypertensive children

Exclusion criteria

* Renal failure * Unstable renal function * Hyperkaliemia

Design outcomes

Primary

Measure	Time frame
Safety assessed from the patient's (parents) complaints and the clinical follow-up	—

Secondary

Measure	Time frame
Acceptability, efficacy, pharmacokinetics	—

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026